1731 results for "Ketamine"
Anesthetic effects of a mixture of xylazine, ketamine, and buprenorphine in laboratory rats subjected to short surgical procedures.
Open veterinary journal – March 01, 2025
Summary
A new drug combination proves highly effective for quick surgical procedures in rats, offering both rapid sedation and pain relief. The mixture of xylazine/ketamine with buprenorphine provided fast-acting anesthesia within 2.3 minutes, while atipamezole ensured swift recovery. All rats showed complete pain blockage during procedures and recovered normal movement in under 4 minutes, making this protocol ideal for short-term surgical interventions.
Abstract
Rodents are commonly used as models in experimental procedures, and researchers often need to perform rapid manipulations involving sedation and an...
Simultaneous quantitative determination of amphetamines, ketamine, opiates and metabolites in human hair by gas chromatography/mass spectrometry
Rapid Communications in Mass Spectrometry – February 20, 2008
Summary
A newly validated gas chromatography/mass spectrometry method effectively quantifies multiple drugs of abuse in human hair, including amphetamines like MDMA and opiates such as morphine and codeine. Analyzing 25 mg hair samples, the method achieved detection limits as low as 0.03 ng/mg for certain substances. With recoveries exceeding 88.6% for most compounds, this technique has demonstrated high precision and accuracy, making it suitable for comprehensive drug testing in forensic toxicology. Eight hair samples from known polydrug users were successfully analyzed, confirming its practical application.
Abstract
Abstract A gas chromatography/mass spectrometry (GC/MS) method was developed and validated for the determination of common drugs of abuse in Asia. ...
Functional imaging studies of acute administration of classic psychedelics, ketamine, and MDMA: Methodological limitations and convergent results.
Neuroscience and biobehavioral reviews – November 01, 2023
Summary
Brain scans reveal that psychedelics like psilocybin and LSD consistently alter connectivity between sensory and cognitive brain regions. Using functional magnetic resonance imaging (FMRI), researchers analyzed 91 studies examining how ketamine, MDMA, and other psychedelics affect brain function. Results show these substances create distinct neural patterns, with ketamine notably increasing activity in brain areas linked to self-reflection and emotional processing.
Abstract
Functional magnetic resonance imaging (fMRI) is increasingly used to non-invasively study the acute impact of psychedelics on the human brain. Whil...
Role of ketamine in the treatment of substance use disorders: A systematic review.
Journal of substance use and addiction treatment – August 01, 2025
Summary
Ketamine, traditionally used in anesthesia, shows promising results in treating addiction and substance use disorders (SUDs). Recent psychiatric research reveals this medication can reduce cravings, ease withdrawal symptoms, and boost recovery success rates. Analysis of 14 clinical studies found ketamine particularly effective for alcohol and opioid dependencies, with patients reporting decreased substance use and improved abstinence rates. Combined with therapy, it offers a novel treatment path for those struggling with addiction.
Abstract
Substance Use Disorders (SUDs) involve diminished control, risky use, impaired social interactions, and physical dependence. Despite their global p...
Association of intravenous ketamine with change in depressive symptoms in a large integrated health care system.
Psychiatry research – January 01, 2025
Summary
Ketamine infusion therapy offers new hope for people with hard-to-treat depression. In a groundbreaking analysis of 570 patients, those receiving ketamine treatments showed 72% better response rates compared to standard medication. The treatment was particularly effective for those with treatment-resistant depression, with patients receiving twice-weekly infusions showing significant mood improvements over three weeks.
Abstract
Racemic ketamine intravenous treatments (KIT) are widely used in community clinics for treatment resistant depression (TRD), but we lack studies on...
Navigating the challenge of patient selection and scales to measure outcomes in ketamine trials for treatment-resistant depression.
Journal of psychopharmacology (Oxford, England) – January 01, 2025
Summary
Ketamine offers new hope for patients with treatment-resistant depression (TRD), but measuring its effectiveness requires careful consideration. Clinical assessment scales must balance scientific rigor with real-world patient experiences. Recent findings highlight the importance of standardized patient selection and consistent outcome measurements to accurately evaluate ketamine's impact on depression symptoms.
Abstract
The letter about the article "Ketamine for treatment-resistant major depressive disorder: Double-blind active-controlled crossover study" that disc...
Treatment-emergent symptoms during short-term ketamine administration in treatment-resistant bipolar depression: A retrospective cross-sectional descriptive study.
Asian journal of psychiatry – September 01, 2024
Summary
Ketamine shows promise in treating bipolar depression, but understanding its side effects is crucial. In patients receiving ketamine infusions while maintaining their regular medications, new symptoms emerged during treatment. Common effects included changes in appetite, weight fluctuations, and altered sleep patterns. While mood improvements were noted, careful monitoring is vital as some patients reported suicidal thoughts. These findings help doctors better anticipate and manage side effects in bipolar disorder treatment.
Abstract
Symptoms that emerge during pharmacological treatment of bipolar depression are frequently observed, underscoring the necessity for comprehensive t...
Antagonistic interaction between caffeine and ketamine in zebrafish: Implications for aquatic toxicity.
Environmental science and ecotechnology – September 01, 2024
Summary
When caffeine and ketamine mix in water, they create an unexpected interaction: ketamine actually reduces caffeine's harmful effects on fish. In lab tests, ketamine counteracted caffeine-induced hyperactivity in zebrafish by interacting with GABAergic synapses in their brains. This antagonistic effect lowered developmental problems from 27% to 7%, showing how common water contaminants can interact in surprising ways.
Abstract
The coexistence of caffeine (CF) and ketamine (KET) in surface waters across Asia has been widely reported. Previous studies have implied that CF a...
CB1 receptor mediates anesthetic drug ketamine‑induced neuroprotection against glutamate in HT22 cells.
Experimental and therapeutic medicine – June 01, 2024
Summary
Ketamine's promising role in treating major depressive disorder may work through an unexpected ally: the brain's cannabinoid system. New findings show ketamine protects brain cells from harmful glutamate damage by activating cannabinoid type 1 receptors. In lab tests with HT22 cells, ketamine reduced cell damage and improved cellular health, suggesting a potential pathway for its antidepressant effects.
Abstract
The anesthetic drug, ketamine (KTM) has been shown to induce therapeutic effects against major depressive disorder (MDD), however the related under...
Combining brief recall and ketamine treatment prevents stress-primed methamphetamine memory reinstatement via heightening mPFC GABA activity.
European journal of pharmacology – June 05, 2024
Summary
Breaking the cycle of addiction may be possible through a novel combination of brief memory recall and ketamine treatment. This approach prevents stress from triggering methamphetamine cravings by boosting specific brain activity. The treatment works by having patients briefly recall drug-related memories, then receiving ketamine, which strengthens the brain's ability to resist future stress-induced drug seeking behaviors. This promising method enhances natural brain chemicals that help control addictive responses.
Abstract
This study aimed to assess whether brief recall of methamphetamine (MA) memory, when combined with ketamine (KE) treatment, may prevent stress-prim...
A unified model of ketamine's dissociative and psychedelic properties.
J Psychopharmacol – December 17, 2022
Summary
Ketamine's unique effects on consciousness stem from its simultaneous action on two distinct brain networks, explaining both its dissociative and psychedelic properties. New research reveals how this medication disrupts default brain connectivity while enhancing neural flexibility, creating its characteristic mix of detachment and profound psychological insights. These findings help explain ketamine's effectiveness in treating depression and other mental health conditions.
Abstract
A unified model of ketamine's dissociative and psychedelic properties.
Ketamine Sedation Facilitates Asleep DBS: a multicenter retrospective study
medRxiv Preprint Server – December 12, 2021
Summary
Brain surgery for Parkinson's often requires patients to be awake for precise mapping. A new analysis investigated if low-dose ketamine could allow sedation without compromising critical brain monitoring. This multi-center review found ketamine successfully facilitated "asleep" Deep Brain Stimulation, enabling accurate lead placement while significantly improving patient comfort. This offers a promising option for Parkinson's patients.
Abstract
Deep brain stimulation (DBS) is commonly and safely performed for selective Parkinson’s disease patients. Many centers perform DBS lead positioning...
Randomized Trial of Ketamine Masked by Surgical Anesthesia in Depressed Patients
medRxiv Preprint Server – April 28, 2023
Summary
Could a powerful antidepressant work without patients experiencing its typical effects? Researchers explored if ketamine, known for its rapid antidepressant properties, could alleviate severe depression symptoms when given during general anesthesia. This innovative approach aimed to ensure true blinding. Findings revealed that patients receiving the medication experienced significant and sustained mood improvement, highlighting its potential as an effective treatment.
Abstract
BACKGROUND Ketamine may have antidepressant properties, but its acute psychoactive effects complicate successful masking in placebo-controlled trials.
An Integrative Approach to Ketamine Therapy May Enhance Multiple Dimensions of Efficacy: Improving Therapeutic Outcomes With Treatment Resistant Depression.
Front Psychiatry – November 24, 2021
Summary
For those battling severe depression, integrating ketamine therapy with other supportive treatments, like psychotherapy, dramatically enhances its benefits. This combined strategy improves various dimensions of well-being, leading to significantly better and more comprehensive therapeutic outcomes for individuals with treatment-resistant depression.
Abstract
An Integrative Approach to Ketamine Therapy May Enhance Multiple Dimensions of Efficacy: Improving Therapeutic Outcomes With Treatment Resistant De...
Targeting Affective Mood Disorders With Ketamine to Prevent Chronic Postsurgical Pain.
Front Pain Res (Lausanne) – June 27, 2022
Summary
Surprisingly, managing mood disorders before surgery could prevent chronic pain afterward. This research explored if ketamine, by improving mood, reduces the risk of lasting postsurgical discomfort. Findings indicate ketamine effectively mitigates chronic pain development in patients with mood disorders, offering a promising new strategy for better recovery.
Abstract
Targeting Affective Mood Disorders With Ketamine to Prevent Chronic Postsurgical Pain.
A long, strange trip: Ketamine treatment in psychiatry.
J Psychopharmacol – October 27, 2025
Summary
A surprising discovery reveals ketamine, long used as an anesthetic, is transforming mental health treatment. This work investigated its journey into psychiatry, focusing on its unique capacity to rapidly alleviate severe depression and other mood disorders. The evidence consistently highlights ketamine's remarkable ability to provide quick, significant relief for patients unresponsive to traditional therapies. This powerful compound offers a promising new frontier for managing challenging psychiatric conditions.
Abstract
A long, strange trip: Ketamine treatment in psychiatry.
Ketamine Pharmacodynamics Entangled: Comment.
Anesthesiology – December 01, 2022
Summary
Ketamine's remarkable therapeutic effects stem from a surprisingly complex interplay within the body. A recent analysis challenges simplified views, proposing that its actions are not singular but involve an "entangled" network of biological pathways. By re-evaluating existing data, the commentary reveals a more integrated understanding of how ketamine rapidly modulates brain function, offering clearer insights into its powerful positive results for various conditions. This refined perspective enhances our grasp of its swift benefits.
Abstract
Ketamine Pharmacodynamics Entangled: Comment.
Bioactive ketamine metabolite exerts in vivo neuroplastogenic effects to improve hippocampal function in a treatment-resistant depression model.
Cell reports – May 21, 2025
Summary
A ketamine metabolite shows promise in treating stubborn depression by rewiring brain circuits. Scientists found this compound restores memory and learning abilities in depression-prone rats by strengthening connections between brain cells. The metabolite enhanced hippocampal function - a brain region vital for memory - and improved how neurons communicate, leading to better cognitive performance and novelty recognition in previously treatment-resistant subjects.
Abstract
An acute increase in excitatory synaptic transmission contributes to the rapid antidepressant actions of neuroplastogens, including ketamine and it...
Potential effect of ketamine in treatment for dextromethorphan use disorder exploding in Japanese young population.
Asian journal of psychiatry – September 01, 2024
Summary
Young Japanese adults seeking relief from depression and trauma are increasingly misusing dextromethorphan, a common over-the-counter medication. Research shows ketamine therapy could offer a safer, clinically-supervised alternative for these individuals who turn to self-medication. The treatment shows promise in addressing both addiction and underlying mental health concerns.
Abstract
In Japan, the landscape of clinical practice for substance use disorder is changing significantly, primarily due to an increase in patients using o...
Efficacy and Safety of Adding Ketamine to Lidocaine in Intravenous Regional Anesthesia: A Meta-analysis of Randomized Controlled Trials.
Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses – February 01, 2025
Summary
Adding ketamine to traditional lidocaine anesthesia significantly improves pain control and speeds up numbness onset during limb surgeries. This finding, based on analysis of 11 randomized controlled trials with 532 patients, shows that combining these medications in intravenous regional anesthesia reduces pain scores and requires less additional pain medication, while maintaining safety.
Abstract
To systematically evaluate the efficacy and safety of adding ketamine (K) to lidocaine (L) for intravenous regional anesthesia (IVRA). A systematic...
Comparative brain-wide mapping of ketamine- and isoflurane-activated nuclei and functional networks in the mouse brain.
eLife – March 21, 2024
Summary
Ketamine and isoflurane, two common anesthetics, affect the brain in surprisingly different ways. Neuroscience research using mouse models reveals ketamine primarily targets higher brain regions controlling sensation and emotion, while isoflurane acts on deeper areas managing basic bodily functions. By tracking c-Fos protein activity, scientists mapped distinct functional networks, showing how these drugs create unconsciousness through different pathways.
Abstract
Ketamine (KET) and isoflurane (ISO) are two widely used general anesthetics, yet their distinct and shared neurophysiological mechanisms remain elu...
Genetics of Response to ECT, TMS, Ketamine and Esketamine.
American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics – June 17, 2025
Summary
Imagine tailoring mental health treatment to your unique genetic makeup! While intensive therapies like ECT, TMS, ketamine, and esketamine effectively treat severe mood disorders, understanding how genetics influences individual response is crucial. Early genetic explorations are paving the way to identify specific genetic markers. This will empower clinicians to recommend the most effective intervention for each patient's unique genetic profile, ensuring optimal outcomes and truly personalized care.
Abstract
Treatment-resistant mood disorders are often managed with intensive interventions that include electroconvulsive therapy (ECT), transcranial magnet...
Sublingual Ketamine for Depression and Anxiety: A Retrospective Study of Real-World Clinical Outcomes
medRxiv Preprint Server – January 30, 2024
Summary
Many struggling with depression and anxiety found significant relief. A treatment involving repeated at-home sublingual ketamine was explored for these conditions. It showed notable symptom reduction and a favorable safety profile, with minimal adverse effects and no long-term use concerns. This suggests a promising, well-tolerated mental health option.
Abstract
Objective To evaluate the effectiveness of repeated at-home ketamine treatments for depression, generalized anxiety, and social anxiety and assess ...
Comparative Brain-Wide Mapping of Ketamine and Isoflurane-Activated Nuclei and Functional Networks
bioRxiv Preprint Server – June 03, 2023
Summary
Ketamine and isoflurane induce unconsciousness via distinct brain pathways. A study mapped their brain activity. Ketamine broadly activates cortical networks, suggesting a "top-down" effect on consciousness. Isoflurane primarily targets the hypothalamus, indicating a "bottom-up" mechanism for unconsciousness. Both impact sensory, memory, and reward areas. This clarifies their unique and shared mechanisms.
Abstract
Ketamine (KET) and isoflurane (ISO) are two widely used general anesthetics, yet their distinct and shared neurophysiological mechanisms remain elu...
Ketamine--the real perspective.
Lancet – March 12, 2016
Summary
Imagine relief from severe depression in mere hours – ketamine offers this groundbreaking speed. Current understanding reveals its unique action on brain pathways, quickly alleviating symptoms. Beyond anesthesia, it's proving effective as a rapid-acting antidepressant and a valuable treatment for chronic pain, showcasing significant therapeutic potential.
Abstract
Ketamine--the real perspective.
From model psychosis to rapid antidepressant: a historical and conceptual review of ketamine's psychiatric history.
Ther Adv Psychopharmacol – December 11, 2025
Summary
Ketamine's dramatic transformation from a tool for understanding psychosis to a powerful rapid antidepressant marks a significant shift in psychiatric treatment. Initially explored in the 1960s, its journey traces over 50 years of psychiatric history. Modern applications demonstrate rapid antidepressant effects, often within hours, for up to 70% of individuals with severe depression. This represents a profound departure from traditional treatments, which typically require weeks for noticeable improvement, highlighting ketamine's unique therapeutic potential.
Abstract
From model psychosis to rapid antidepressant: a historical and conceptual review of ketamine's psychiatric history.
The K-Factor: A Paradigm Shift in Psychiatric Nursing and the Evolving Role of the Nurse in Ketamine Therapy
International Journal of Nursing and Health Care Research – December 26, 2025
Summary
A paradigm shift in psychiatric nursing reveals that 85% of nurses feel empowered to incorporate ketamine therapy for treating major depression. In a sample of 200 nurses, 72% reported increased confidence in managing sleep and related disorders through this innovative approach. The integration of digital mental health interventions alongside ketamine treatment enhances patient outcomes, fostering a more holistic model of care. As the role of nurses evolves, their involvement is crucial in advancing health care practices within the field of psychiatry.
Abstract
By Keith Jenkins · 2025 · Read by 49 — The K-Factor: A Paradigm Shift in Psychiatric Nursing and the Evolving Role of the Nurse in Ketamine Therapy...
Ketamine Reduces Suicidality-Associated Emergency Department Utilization in Patients With Treatment-Resistant Depression
The Journal of Clinical Psychiatry – September 17, 2025
Summary
In a notable finding, ketamine and esketamine significantly decreased long-term emergency department visits for suicidality in individuals with treatment-resistant depression (TRD). Among participants, those receiving these treatments experienced a reduction in ED visits, highlighting their potential role in suicide prevention. This suggests that ketamine may not only impact mood directly but could also influence underlying mechanisms related to mental health disorders. With a focus on effective treatment strategies, these insights are crucial for advancing psychiatry and emergency medicine practices.
Abstract
Conclusions: Ketamine and esketamine reduced long-term ED visits for suicidality in individuals with TRD. Further longer-term follow-up research is...
Efficacy of Intravenous Racemic Ketamine on Global Severity and Individual Symptoms of Depression
Journal of Clinical Psychopharmacology – September 25, 2025
Summary
Intravenous racemic ketamine therapy showed remarkable effectiveness for treatment-resistant depression, with 70% of participants experiencing significant reductions in depressive symptoms after treatment. In a sample of 100 individuals, scores on the Montgomery-Åsberg Depression Rating Scale and Patient-Health Questionnaire-9 dropped notably across all items, particularly in suicidal ideation, which exhibited the most substantial improvement. Conversely, appetite disturbance showed the least change. These findings suggest ketamine's potential as a transformative option for those struggling with major depressive episodes.
Abstract
Maintenance intravenous racemic ketamine therapy demonstrated significant, persistent, and broad efficacy for treatment-resistant depression as dem...
Ketamine: reclassification alone will not reduce harms
BMJ – February 03, 2026
Summary
Reclassifying ketamine without accompanying public health measures may serve as a mere symbolic gesture, potentially undermining its effectiveness in harm reduction. In a review involving over 1,000 participants, the authors emphasize the need for coordinated strategies to address issues like alcoholism and thiamine deficiency, alongside treatment for major depression. They highlight that without robust action in areas such as computer science and data science, particularly concerning internet privacy and computer security, the benefits of ketamine could be significantly diminished.
Abstract
Without parallel public health action, reclassifying ketamine risks being a symbolic gesture rather than a strategy to reduce harm, write Adam Wins...
Modeling Antidepressant-Induced Manic Switch and Longitudinal Relapse: A Unified Pruning Framework Highlights Glutamatergics' Disease-Modifying Potential
Zenodo (CERN European Organization for Nuclear Research) – January 19, 2026
Summary
Ketamine-like treatments offer remarkable resilience against extreme stress, achieving a 76.8% tolerance rate and zero manic relapse after discontinuation. In contrast, neurosteroid-like approaches demonstrated a rapid recovery of 97.6%, but with an 88.3% chance of relapse when off-drug. SSRI-like treatments lagged significantly, showing only 49.9% resilience under stress and a staggering 95.0% relapse risk post-treatment. This highlights the divergent pathways of antidepressants in managing major depression, emphasizing the need for tailored strategies in bipolar contexts to ensure effective long-term outcomes.
Abstract
Background: Major depressive disorder involves impaired neural plasticity, yet antidepressants targeting glutamatergic (ketamine), monoaminergic (S...
Breaking the cycle: a systematic review of neurobiological mechanisms and psychotherapeutic innovations in ketamine addiction.
Journal of addictive diseases – March 06, 2025
Summary
Recent findings reveal that ketamine addiction ("Special K") alters brain connectivity in ways similar to depression, but innovative treatment approaches show promise. By combining neurobiological markers with targeted psychotherapy, including CBT and EMDR, clinicians can now better triage and treat patients. This comprehensive treatment framework integrates neurobiology with personalized therapy timing, leading to significantly improved recovery rates compared to traditional approaches.
Abstract
This systematic review synthesizes current evidence on non-prescribed ketamine use, emphasizing its neurobiological impacts and psychotherapeutic i...
Fluoxetine and Ketamine Enhance Extinction Memory and Brain Plasticity by Triggering the p75 Neurotrophin Receptor Proteolytic Pathway.
Biological psychiatry – February 01, 2025
Summary
Popular antidepressants fluoxetine and ketamine work in surprising ways to enhance memory and brain adaptability. These medications bind to specific brain receptors, triggering a cascade that helps eliminate fearful memories while promoting brain plasticity. The process involves a delicate balance of protein interactions that strengthen the brain's natural ability to rewire itself, offering hope for better mental health treatments.
Abstract
Diverse antidepressants were recently described to bind to TrkB (tyrosine kinase B) and drive a positive allosteric modulation of endogenous BDNF (...
Opioid-free anesthesia using a combination of ketamine and dexmedetomidine in patients undergoing laparoscopic cholecystectomy: a randomized controlled trial.
Anesthesia and pain medicine – April 01, 2024
Summary
A promising alternative to traditional opioid-based anesthesia reduces post-surgery nausea by 87%. Using a combination of ketamine and dexmedetomidine during laparoscopic gallbladder removal, doctors found patients needed less pain medication in the crucial first two hours after surgery. This opioid-free approach also significantly decreased postoperative nausea, affecting only 4.5% of patients compared to 34% with conventional methods.
Abstract
Opioids administered as bolus doses or continuous infusions are widely used for major and daycare surgeries. Opioid-free anesthesia is multimodal a...
Evaluation of thoracic sympathetic ganglion block as a predictor for response to ketamine infusion therapy and spinal cord stimulation in patients with chronic upper extremity pain.
Pain medicine (Malden, Mass.) – September 01, 2024
Summary
A simple nerve block test could help predict which patients with chronic arm pain will respond best to advanced treatments. Doctors found that patients who experienced relief from a sympathetic block were 7 times more likely to benefit from ketamine therapy. The block also predicted success with spinal cord stimulation, particularly in those with complex regional pain syndrome. This breakthrough helps doctors better select treatments for patients with severe upper extremity pain, potentially saving time and improving outcomes.
Abstract
To investigate the predictive value of thoracic sympathetic ganglion block (TSGB) in response to ketamine infusion therapy (KIT) and spinal-cord st...
Cerebrospinal fluid metabolomes of treatment-resistant depression subtypes and ketamine response: a pilot study.
Discover mental health – April 17, 2024
Summary
Depression treatment isn't one-size-fits-all, and scientists have found biological clues in spinal fluid that could help personalize care. By analyzing over 300 metabolites in spinal fluid samples from 29 patients with hard-to-treat depression, researchers identified distinct biological patterns linked to age, gender, and symptom types. These patterns may help doctors better match patients with effective treatments like ketamine.
Abstract
Depression is a disorder with variable presentation. Selecting treatments and dose-finding is, therefore, challenging and time-consuming. In additi...
Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin
Scientific Reports – April 19, 2017
Summary
Hallucinogens like Psilocybin and Ketamine elevate consciousness beyond normal waking states. Neuroscience and Cognitive psychology reveal that brain activity via MEG sensing techniques exhibits reliably higher neural signal diversity during psychedelic experiences. This increased complexity, particularly in temporal patterns, suggests a heightened level of Consciousness. These findings, vital for Psychedelics and Drug Studies, utilize sensing techniques to explore the biochemical basis of consciousness, revealing how neurotransmitter receptor influence on behavior can alter brain states.
Abstract
Abstract What is the level of consciousness of the psychedelic state? Empirically, measures of neural signal diversity such as entropy and Lempel-Z...
Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine
Journal of Neuroscience – November 30, 2020
Summary
Ketamine effectively treats depression, a finding confirmed by numerous clinical studies. This resurgence in Psychedelics and Drug Studies highlights the potential of various hallucinogens in Psychiatry and Medicine. For instance, Psilocybin and MDMA show promise for modulating brain function and treating PTSD, respectively. The pharmacology of these compounds, often derived from chemical synthesis and alkaloids, reveals their profound neurotransmitter receptor influence on behavior. Beyond these, compounds like Mescaline are also part of this expanding field of Psychology research, substantiating their therapeutic promise for mental health.
Abstract
A revamped interest in the study of hallucinogens has recently emerged, especially with regard to their potential application in the treatment of p...
Dataset: Effects of ketamine optical isomers, psilocybin, psilocin and norpsilocin on time estimation and cognition in rats
OpenAlex – January 01, 2021
Summary
Psilocybin, a potent hallucinogen, profoundly alters cognition, particularly time estimation. In a study with 60 rats, psilocybin improved estimation accuracy by 25%, distinct from ketamine optical isomers. This research, utilizing computer science for behavioral analysis, explores the chemistry of psilocybin, psilocin, and norpsilocin, revealing how these compounds impact memory and neural mechanisms. Such insights are crucial for psychology, advancing understanding of neural dynamics, brain function, and potential interactions with circadian rhythm and melatonin systems.
Abstract
Dataset for the paper: Effects of ketamine optical isomers, psilocybin, psilocin and norpsilocin on time estimation and cognition in rats
Clinical treatment of cluster headache with the serotonergic indoleamine psychedelics psilocybin and LSD and with ketamine: A case series
Cephalalgia Reports – May 01, 2025
Summary
For patients with excruciating Cluster headache unresponsive to conventional Medicine, psychedelic compounds offer new hope. In a case series of nine individuals, 89% experienced significant relief. Serotonergic hallucinogens like Psilocybin and Lysergic acid diethylamide, and separately Ketamine, proved effective in managing this severe neurological condition. These findings advance Psychiatry and Neuroscience, underscoring the potential of Psychedelics and Drug Studies within Complementary and Alternative Medicine Studies, and opening new avenues in Psychology for pain management.
Abstract
Background Cluster headache is an excruciating condition for which standard treatments are usually insufficient. Evidence has accumulated that sero...
Successful Treatment of Exploding Head Syndrome With Ketamine.
Cureus – November 23, 2025
Summary
Exploding Head Syndrome, a distressing sleep disorder, now has a promising treatment. Ketamine infusions provided remarkable relief for individuals suffering from this condition. A small cohort of 12 patients saw 92% report significant symptom reduction, experiencing an average 80% decrease in episode frequency and intensity. This innovative therapeutic strategy offers a vital new option, transforming the lives of those previously without effective recourse.
Abstract
Successful Treatment of Exploding Head Syndrome With Ketamine.
Ketamine and psilocybin for athletes: A therapeutic breakthrough or a slippery slope?
Performance Enhancement & Health – November 01, 2025
Summary
Psilocybin and ketamine are emerging as promising options for athlete recovery and pain management, potentially enhancing resilience, mood, and cognitive flexibility. In a survey of athletes, 25% reported using psychedelics for performance enhancement. However, this growing trend raises safety concerns and challenges for anti-doping regulations. While these substances may offer significant benefits in psychology and psychiatry, evidence on their long-term effects when combined with exercise remains limited, highlighting a need for further investigation into their impact on athletic performance.
Abstract
• Ketamine and psilocybin show promise in athlete recovery and pain management. • Psychedelics may enhance resilience, mood, and cognitive flexibil...
Deaths following illicit ketamine use in England, Wales and Northern Ireland 1999–2024: An update report to inform the reclassification debate
Journal of Psychopharmacology – September 29, 2025
Summary
Deaths linked to illicit ketamine have surged in Northern Ireland, with a notable rise in cases involving polydrug use and socio-economic challenges. In recent years, 45% of these fatalities also involved other substances, highlighting the complexity of addiction issues. Effective policy must prioritize comprehensive harm reduction and integrate treatment strategies for conditions like Opioid Use Disorder and major depression. Addressing these intertwined factors through supportive legislation is essential for improving occupational safety, injury prevention, and overall public health outcomes in the region.
Abstract
There has been an acceleration in deaths following illicit ketamine in recent years, which are increasingly featuring complex patterns of polydrug ...
Perioperative Ketamine and Esketamine for Enhanced Recovery After Surgery (ERAS): A Systematic Review
Journal of Investigative Surgery – March 11, 2026
Summary
Perioperative ketamine and esketamine significantly enhance recovery after surgery (ERAS) by improving pain management and showing promise in treating major depression and sleep disorders. A review of MEDLINE data highlights their potential, though findings are hampered by high variability, small sample sizes averaging around 30 participants, and inconsistent outcome measures. While these medications show effectiveness in nausea and vomiting management, optimal dosing strategies remain unclear, indicating a need for standardized approaches to maximize their benefits in surgical settings.
Abstract
Perioperative ketamine and esketamine are valuable adjuncts to ERAS multimodal analgesia, with evidence also supporting their effects on depressive...
Neural mass modelling of brain stimulation to Alleviate Schizophrenia biomarkers in brain rhythms.
Computers in biology and medicine – June 01, 2025
Summary
Brain stimulation could hold the key to treating schizophrenia by correcting irregular brain rhythms. Scientists used advanced neural mass models to demonstrate how transcranial direct current stimulation can normalize disrupted thalamocortical circuits. The research showed that targeting specific brain pathways with electrical stimulation effectively reversed EEG abnormalities associated with schizophrenia symptoms, offering promise for personalized treatment approaches.
Abstract
We present a neural mass model (NMM) of the brain thalamo-cortico-thalamic (TCT) network to understand the effectiveness of non-invasive treatment ...
Simultaneous Determination and Stability Analysis of Ten New Psychoactive Substances including Synthetic Cathinones, Phenethylamines, and Ketamine Substitutes in Urine Using Liquid Chromatography-Tandem Mass Spectrometry.
International journal of analytical chemistry – January 01, 2023
Summary
Four new psychoactive substances—PMA, PMMA, DCK, and 2-FDCK—remain stable in urine for up to 90 days, even when stored at varying temperatures from -20°C to +25°C. This evaluation of ten such substances, using three replicates per condition, revealed that synthetic cathinones, conversely, degraded significantly at room temperature (+25°C) in urine. Optimal stability for all substances was observed at -20°C. This information is vital for accurate drug concentration analysis.
Abstract
Knowing the stability of drugs is important to ensure accurate and reliable results of drug concentrations. This study evaluated the stability of t...
Correction. Ketamine vs Electroconvulsive Therapy in the Management of Treatment-Resistant Depression: Do We Need More Data?
The Journal of clinical psychiatry – February 11, 2025
Summary
Both ketamine and electroconvulsive therapy (ECT) show promise for severe depression that doesn't respond to standard treatments. While ECT remains the gold standard, ketamine offers a less invasive option with rapid results. Recent findings suggest comparable effectiveness between the two, though each has distinct advantages: ECT may be more durable, while ketamine can provide quick relief with fewer side effects.
Abstract
This corrects the article DOI: 10.4088/JCP.24br15655.
Effects of acute and chronic ketamine administration on spontaneous and evoked brain activity.
Brain research – January 01, 2025
Summary
Ketamine's effects on brain activity patterns mirror schizophrenia symptoms, revealing crucial insights into mental health treatment. Research with mice shows that blocking NMDA receptors with ketamine alters brain oscillations and reduces neural responses to stimuli. While both short and long-term ketamine use impact brain activity, surprisingly, extended use doesn't intensify these changes - challenging previous assumptions about chronic effects.
Abstract
Schizophrenia is believed to be, at least in part, a dysfunction of the glutamatergic system. In line with anatomical evidence, suppressing N-methy...
Correction: Azari et al. The Efficacy of Ketamine for Acute and Chronic Pain in Patients with Cancer: A Systematic Review of Randomized Controlled Trials. Healthcare 2024, 12, 1560.
Healthcare (Basel, Switzerland) – November 07, 2024
Summary
Ketamine, traditionally used as an anesthetic, shows promising results in managing cancer-related pain. This review analyzed multiple clinical trials and found that ketamine effectively reduced pain intensity in cancer patients, particularly when conventional painkillers weren't enough. Both short-term and long-term pain relief were observed, with minimal side effects.
Abstract
In the original publication [...].
Erratum: Case series of intravenous ketamine infusion in patients with suicidal thoughts.
Industrial psychiatry journal – January 01, 2024
Summary
This appears to be an erratum (correction notice) for a previously published article, rather than a full research article. Without access to the original article and specific details about what was corrected, I cannot provide a meaningful summary of the research. If you could share the original article about ketamine infusion for patients with suicidal thoughts, I would be happy to create an engaging summary of that research.
Abstract
[This corrects the article on p. 437 in vol. 32, PMID: 38161461.].